Shanghai Bio-Forum Focuses On Patent Protection And Drug Pricing
This article was originally published in PharmAsia News
Executive Summary
Patent protection and drug pricing were hot issues at the recent Conference of Chinese Biopharmaceutical Association and Shanghai Bio-Forum. Delegates agreed that patent protection is a prerequisite of collaboration and represents a key factor that is irreplaceable in the trend of global cooperation. China's laws and regulations on patent and intellectual property protection are well-received but overseas investors and partners expressed concern on the effectiveness of their long-term implementation. Opportunities for collaboration abound in the biopharmaceutical process and China offers the common language of an internationally recognized GMP system. (Click here for more - Chinese Language)
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.